🇺🇸 FDA

Intelligence Platform

Patents

Browse 45 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12377090

Methods for treating neutropenia

X4 Pharmaceuticals, Inc. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331126

OX40-binding polypeptides and uses thereof

Inhibrx Biosciences, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12285424

Methods for treating neutropenia

X4 Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227584

Multivalent and multispecific OX40-binding fusion proteins

Inhibrx Biosciences, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162937

Methods of treating an inflammatory disorder by administering an antibody which binds to a

The Board of Regents of the University of Texas System · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115156

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012459

OX40-binding polypeptides and uses thereof

Inhibrx, Inc. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11912758

Methods of treating metastasis, including inhibiting bone cancer metastasis, by administer

The Board of Regents of the University of Texas System · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845937

RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

Arrowhead Pharmaceuticals, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11780837

CXCR4 inhibitors and uses thereof

X4 Pharmaceuticals, Inc. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672793

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613560

Bicyclic peptide ligands specific for OX40

BicycleTx Limited · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479770

Use of p38 inhibitors to reduce expression of DUX4

Fulcrum Therapeutics, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11357742

Methods for treating cancer

X4 Pharmaceuticals, Inc. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11337969

Methods for treating cancer

X4 Pharmaceuticals, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11332470

CXCR4 inhibitors and uses thereof

X4 Pharmaceuticals, Inc. · Granted Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306088

CXCR4 inhibitors and uses thereof

X4 Pharmaceuticals, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11291659

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286305

Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleot

Dyne Therapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11219621

Methods for treating immunodeficiency disease

X4 Pharmaceuticals, Inc. · Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208479

CX43 hemichannel antibodies and methods of use

The Board of Regents of the University of Texas System · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117972

Multivalent and multispecific OX40-binding fusion proteins

Inhibrx, Inc. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11111309

Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferri

Dyne Therapeutics, Inc. · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11045461

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted